by CSPC issued a statement that the new mRNA vaccine developed by the company has been included in emergency use by health regulators. This is the first mRNA-based COVID-19 vaccine approved by China. Previously, the new crown vaccines approved by China were mainly inactivated vaccines. Vaccines made from killed pathogens have a low degree of processing of antigenic components, require multiple vaccinations and have a short-lasting immune effect. An mRNA vaccine is a vaccine that uses a molecular copy of messenger RNA (mRNA) to generate an immune response. It can be designed and produced quickly and can produce a longer-lasting immune response.
https://doc.irasia.com/listco/hk/cspc/announcement/a230322.pdf
